The overall response rate was 14% as monotherapy and 18.2% when administered in combination with the anti-PD-1 monoclonal antibody cemiplimab in patients with recurrent ovarian cancer (NCT03564340) [48]. Here, PDCD1 is linked to ovarian carcinoma.